Radiation Therapy For Oropharyngeal Squamous Cell Carcinoma
Publication Date: August 1, 2017
Last Updated: March 14, 2022
Recommendations
When is it appropriate to add systemic therapy to definitive RT in the treatment of OPSCC?
In the scenario of stage IVA-B disease?
Concurrent high-dose intermittent cisplatin should be delivered to patients with stage IVA-B OPSCC receiving definitive RT. (Strong, High)
323259
Concurrent cetuximab or carboplatin-fluorouracil should be delivered to patients with stage IVA-B OPSCC receiving definitive RT who are not medically fit for high-dose cisplatin. (Strong, High)
323259
Concurrent weekly cisplatin may be delivered to patients with stage IVA-B OPSCC receiving definitive RT who are not medically fit for high-dose cisplatin, after a careful discussion of patient preferences and the limited prospective data supporting this regimen. (Conditional, Low)
323259
Concurrent cetuximab should not be delivered in combination with chemotherapy to patients with stage IVA-B OPSCC receiving definitive RT. (Strong, High)
323259
Intra-arterial chemotherapy should not be delivered to patients with stage IVA-B OPSCC receiving definitive RT. (Strong, High)
323259
In the scenario of stage III disease?
Concurrent systemic therapy should be delivered to patients with T3 N0-1 OPSCC receiving definitive RT. (Strong, Moderate)
323259
After a careful discussion of patient preferences and the limited evidence supporting its use, concurrent systemic therapy may be delivered to patients with T1-T2 N1 OPSCC receiving definitive RT who are considered at particularly significant risk for locoregional recurrence. (Conditional, Low)
323259
In the scenario of stage I-II disease?
Concurrent systemic therapy should not be delivered to patients with stage I-II OPSCC receiving definitive RT. (Strong, Low)
323259
Overview
Title
Radiation Therapy For Oropharyngeal Squamous Cell Carcinoma
Authoring Organization
American Society for Radiation Oncology